CSL Limited (ASX:CSL) insider Megan Clark bought 175 shares of CSL stock in a transaction on Friday, March 20th. The shares were purchased at an average price of A$283.97 ($201.39) per share, for a total transaction of A$49,694.05 ($35,244.01).
Shares of CSL stock traded up A$17.63 ($12.50) during midday trading on Thursday, reaching A$301.99 ($214.18). 1,907,925 shares of the stock were exchanged, compared to its average volume of 900,202. CSL Limited has a 1 year low of A$189.14 ($134.14) and a 1 year high of A$342.75 ($243.09). The company’s 50 day moving average is A$312.24 and its two-hundred day moving average is A$278.83. The company has a current ratio of 2.19, a quick ratio of 1.00 and a debt-to-equity ratio of 92.27. The firm has a market cap of $137.07 billion and a PE ratio of 68.37.
The company also recently announced a Interim dividend, which will be paid on Thursday, April 9th. Shareholders of record on Thursday, April 9th will be issued a dividend of $1.416 per share. This is an increase from CSL’s previous Interim dividend of $1.20. The ex-dividend date of this dividend is Wednesday, March 11th. This represents a dividend yield of 0.43%. CSL’s dividend payout ratio is 66.33%.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Featured Article: CD Ladder
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.